ALLERGAN INC Form 424B3 October 23, 2006

Filed Pursuant to Rule 424(b)(3) Registration No. 333-136188

PROSPECTUS SUPPLEMENT NO. 8 (TO PROSPECTUS DATED JULY 31, 2006)

\$750,000,000

ALLERGAN, INC. 1.50% CONVERTIBLE SENIOR NOTES DUE 2026 SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES

This Prospectus Supplement No. 8 supplements and amends the Prospectus dated July 31, 2006 (as amended, the Prospectus), relating to the resale from time to time by holders of our 1.50% Convertible Senior Notes Due 2026 and shares of our common stock issuable upon the conversion of the notes of such securities. Such information has been obtained from the selling securityholders. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement.

The information appearing in the table below, as of the date hereof, supplements and amends the information in the table appearing under the heading Selling Securityholders in the Prospectus, and, where the name of a Selling Securityholder identified in the table below also appears in the table in the Prospectus, the information set forth in the table below regarding that Selling Securityholder supercedes the information in the Prospectus:

	PRINCIPAL AMOUNT OF			
	NOTES		COMMON	COMMON
			STOCK	
	BENEFICIALLY	PERCENTAGE	OWNED	STOCK
		OF	PRIOR TO	
	OWNED AND	NOTES	THE	OFFERED
	OFFERED			HEREBY
NAME OF SECURITY HOLDER	HEREBY	OUTSTANDING	OFFERING	(1)
Advent Convertible Master Fund LP	\$ 7,281,000	*	0	57,484
HFR Convertible Arbitrage	631,000	*	0	4,981
Lyxor Convertible Arbitrage Fund	271,000	*	0	2,139
Merrill Lynch, Pierce, Fenner & Smith	942,000	*	0	7,437
San Francisco Public Employees Retirement				
System	1,822,000	*	0	14,385
UBS Securities LLC	7,545,000	*	0	59,569

* Less than one

percent.

(1) The number of shares of common stock offered hereby includes shares of common stock into which the notes are convertible. The number of shares of common stock offered hereby is based on a conversion rate of 7.8952 shares of common stock per \$1,000 principal amount of maturity of the notes. Information concerning other Selling Securityholders will be set forth in prospectus supplements from time to time, if required. The number of shares of common stock owned by the other Selling Securityholders or any future transferee from any such holder assumes that they do not beneficially own any common stock other than common stock into which the notes are convertible at a conversion rate of 7.8952 shares of common stock per \$1,000 principal amount of maturity of the notes.

INVESTING IN THE NOTES OR THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTES INVOLVES A HIGH DEGREE OF RISK. PLEASE CONSIDER THE RISK FACTORS BEGINNING ON PAGE 5 OF THE PROSPECTUS.

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THE

Edgar Filing: ALLERGAN INC - Form 424B3

PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this prospectus supplement is October 23, 2006.